Elpida Therapeutics

We are deeply grateful to California Institute for Regenerative Medicine (CIRM) for their support in raising awareness and providing the funding, guidance, and support needed on our journey to develop treatments for CMT4J and other genetic diseases. -Together, we will turn the impossible into possible!-

We are truly blessed and grateful to have the incredible support and partnership of Fundación Columbus. Without their backing, Elpida would not exist, and the amazing work we are doing would never have been possible. Together, we will make the impossible possible!

📢 Exciting news! Elpida Therapeutics has enrolled the first patients in its groundbreaking Natural History Study for Charcot-Marie-Tooth Disease Type 4J (CMT4J). This crucial research will help shape future treatments and therapies. Read the full press release for more details: https://lnkd.in/gdugbhgU #CMT4J #GeneTherapy #RareDiseases #MedicalResearch #ElpidaTherapeutic California Institute for Regenerative Medicine (CIRM)

Elpida TX is dedicated to expediting life-saving gene therapies and enhancing the lives of children affected by rare diseases. This commitment extends beyond our own programs to encompass all afflicted children worldwide. Thanks to remarkable collaborations at UTSW, Viralgen, Boston Children's, SickKids, Columbus Children's Foundation, Foundation Columbus, CureSPG50 & others, we have opted to release our Pre-IND, IND and Clinical documents for our SPG50 program. As a collective, we hope that these documents will aid others on their program journeys  and inspire them to share their documents, fostering an environment of transparency and cooperation for the advancement of rare disease programs globally. https://lnkd.in/gNynw_NS UT Southwestern Medical Center, Viralgen Vector Core, Boston Children's Hospital, The Hospital for Sick Children, Columbus Children's Foundation, Fundación Columbus, CureSPG50

Thank you California Institute for Regenerative Medicine and BGTC for supporting our programs and funding critical programs for rare diseases. Rare diseases have little to no funding options and we are so thankful for your incredible support!

🌟 On this Rare Disease Day, we honor the resilience and strength of individuals and families living with rare diseases worldwide. At Elpida Therapeutics, we're committed to driving innovation and advancing research to bring hope and support to those in need. Together, let's raise awareness, inspire action, and make a difference. #RareDiseaseDay #ShowYourRare #ElpidaTherapeutics #RareDiseaseAwareness

We are so very humbled and grateful to CIRM for awarding us this incredible $4 million dollar grant. This critical funding will be used towards IND enabling studies to expedite a gene therapy to patients with CMT4J disease. https://lnkd.in/gXthBnCq We would like to thank our incredible partners for supporting us and helping us work towards a treatment for this orphan disease population. Together we will give children living with this terrible disease a better life! Our Partners California Institute for Regenerative Medicine (CIRM) National Center for Advancing Translational Sciences (NCATS) Foundation for the National Institutes of Health CureCMT4J/Talia Duff Foundation Viralgen Vector Core Charles River Laboratories QuatreLabs Clario KO Law Firm Ciitizen DSST UT Southwestern Medical Center Children's Health Stanford University UIowa Neuroscience Institute National Institute of Neurological Disorders and Stroke (NINDS) Columbus Children's Foundation Fundación Columbus #genetherapy , #ClincialTrials, #CTM4J, #Hope

🎉 Exciting News! We are looking forward to exploring our new partnerships with Ciitizen for both CMT4J and SPG50 programs. Their commitment to enhancing patient-directed healthcare, particularly for those living with rare and complex diseases, is truly inspiring. It's time for novel solutions, and together, we can make significant strides in treating rare conditions.

Big News from Elpida Therapeutics!   We're excited to announce the launch of a Natural History Study in Charcot-Marie-Tooth Disease Type 4J (CMT4J) by Elpida Therapeutics. This important study, enrolling 20 participants, aims to deepen our understanding of CMT4J and pave the way for future gene therapy trials.   This initiative underscores our commitment to pioneering healthcare innovation and offering new hope to those affected by this rare condition! https://lnkd.in/geGhuc_s Foundation for the National Institutes of Health, The National Institutes of Health, UT Southwestern Medical Center, Iowa State University, Stanford University, CureCMT4J/Talia Duff Foundation

We express our deep gratitude to KO Law Firm, Brad Schoenfeld, Samantha Pjesky, Lisa McDiarmid & Sara Shelly for being exceptional partners, wholeheartedly supporting Elpida Therapeutics and the children whose lives we aim to improve. We are truly humbled and appreciative of the existence of remarkable individuals and companies that willingly lend a helping hand when called upon. Together we will give children living with these terrible diseases a better life!